Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 May 5:16:1243-1253.
doi: 10.2147/COPD.S292109. eCollection 2021.

Management of Cough in Patients with Chronic Obstructive Pulmonary Disease: Results of the Multicenter Randomized Placebo-Controlled Clinical Trial

Sergey N Avdeev  1 , Alexander A Vizel  2 , Vladimir N Abrosimov  3 , Andrey A Zaicev  4 , Galina L Ignatova  5 , Rustem F Khamitov  2 , Marina P Mikhaylusova  6 , Julia S Shapovalova  7 , Elena F Pavlysh  8 , Basil I Trofimov  9 , Alexander V Emelyanov  10 , Tatiana I Martynenko  11 , Vladimir A Martynenko  12 , Natalia E Kostina  13 , Danila A Chizhov  14 , Olga Yu Chizhova  10 , Natalia A Kuzubova  15 , Elena V Makova  16 , Ekaterina V Makarova  17   18
Affiliations
Randomized Controlled Trial

Management of Cough in Patients with Chronic Obstructive Pulmonary Disease: Results of the Multicenter Randomized Placebo-Controlled Clinical Trial

Sergey N Avdeev et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Background: Chronic cough declines quality of life and increases risk of complications in patients with chronic obstructive pulmonary disease (COPD). Reducing cough severity and associated negative effects is important therapeutic goal in COPD. Rengalin with anti- and protussive activity is based on technologically processed antibodies to bradykinin, histamine and morphine.

Aim: To evaluate efficacy and safety of Rengalin in treatment of cough in patients with COPD.

Methods: Patients (n=238, mean age 64.3±8.2 years) with stable COPD and persistent cough despite maintenance therapy (anticholinergics, beta-2-adrenergic agonists, inhaled corticosteroids) were included and randomized in the study. The severity of cough assessment (according to the "Cough Severity Score"), COPD impact on patient's life (COPD Assessment Test, CAT), and spirometry were performed at screening. Patients took Rengalin or Placebo 2 tablets 2 times daily for 4 weeks. The endpoints were proportion of patients who responded to treatment, dynamics of cough severity, and severity of COPD symptoms. Intention-to-treat (per protocol) analysis was performed.

Results: Positive response to Rengalin was recorded in 83.6 [85.7]% (vs 72.6 [72.7]% in Placebo group, p=0.0422 [p=0.0163]). Double decrease of cough severity was reported in 42.2 [43.8]% in Rengalin group (versus 32.7 [32.7]% in Placebo; p=0.1373 [p=0.0907]). The total CAT score decreased by 3.3±4.2 [3.6±3.9] points (versus 2.5±4.1 [2.5±4.2] in Placebo group); the difference between groups was 0.79±4.16 [1.04±4.02] points (p=0.0870 [p=0.0416]). The number of patients with adverse events (AEs) in Rengalin (n=13) and Placebo (n=12) groups did not have significant differences (p=1.00). No AEs with certain relationship with study drug were registered.

Conclusion: Rengalin is an effective and safe drug in patients with stable COPD and persistent cough, despite stable doses of maintenance therapy according to the GOLD guidelines. Four-week therapy decreases severity of cough by two times in more than 40% of patients.

Trial registration: ClinicalTrials.gov (id: NCT03159091).

Keywords: Rengalin; chronic obstructive pulmonary disease; cough; cough management; treatment.

PubMed Disclaimer

Conflict of interest statement

Avdeev S.N., MD, PhD, professor, Vizel’ A.A., MD, PhD, professor, Abrosimov V.N., MD, PhD, professor, Ignatova G.L., MD, PhD, professor, Khamitov R.F., MD, PhD, professor, Mikhaylusova M.P., MD, PhD, Shapovalova Yu.S., MD, PhD, Pavlysh E.F., MD, PhD, Trofimov V.I., MD, PhD, professor, Emel’yanov A.V., MD, PhD, professor, Martynenko T.I., MD, PhD, professor, Martynenko V.A., MD, PhD, Kostina N.E., MD, PhD, Chizhov D.A., MD, Chizhova O.Yu., MD, PhD, professor, Kuzubova N.A., MD, PhD, Makova E.V., MD, PhD, and Makarova E.V., MD, PhD received an investigator grant from Materia Medical Holding to conduct the clinical trial of Rengalin mentioned in this article. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flow diagram.
Figure 2
Figure 2
Percentage of patients responsive to treatment. PP analysis data. *p=0.016.
Figure 3
Figure 3
The change of the total CAT score after 4 weeks of treatment. PP analysis data. *p=0.0416.
See this image and copyright information in PMC

References

    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD; 2020. [Internet]. Available from: https://goldcopd.org/gold-reports/. Accessed December10, 2019.
    1. Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):67. doi:10.1186/s12931-017-0548-3 - DOI - PMC - PubMed
    1. Jones PW, Brusselle G, Dal Negro RW, et al. Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe. Prim Care Respir J. 2012;21(3):329–336. doi:10.4104/pcrj.2012.00065 - DOI - PMC - PubMed
    1. Global Initiative for Chronic Obstructive Lung Disease. World lung day; September 25, 2019. Available from: https://goldcopd.org/world-lung-day-2019-respiratory-groups-unite-to-cal.... Accessed April16, 2021.
    1. Wacker ME, Kitzing K, Jörres RA, et al. The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort. Int J Chronic Obstr Pulm Dis. 2017;12:3437. doi:10.2147/COPD.S141852 - DOI - PMC - PubMed

Substances

Associated data